ClinicalTrials.gg
CompletedNCT01688037Updated Nov 8, 2017Results posted

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

A Phase 2 interventional study of NBI-98854 and NBI-98854 in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 51 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
6th of 14
109 · median 101
Started
2012
with 1 other
Phase 2
4 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 2, and was the 3rd registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Read the detailed description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for up to 2 weeks. The study will also allow for an evaluation of the efficacy of NBI-98854 50 mg once daily for up to 6 weeks and the safety and tolerability of NBI 98854 50 mg once daily for up to 12 weeks.

The double-blind placebo-controlled treatment period the study has three arms:

  • NBI-98854 50 mg once daily for 6 weeks
  • NBI-98854 100 mg once daily for 2 weeks followed by 50 mg once daily for the remaining 4 weeks
  • placebo

At the end of the 6-week placebo-controlled double-blind treatment period, subjects will continue in the study for an additional 6-week open-label period where all subjects who have completed the double-blind treatment period will receive NBI-98854 50 mg once daily. Two and four weeks after the last dose of study drug, follow-up assessments will be performed.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of schizophrenia or schizoaffective disorder and a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening.
  • Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status.
  • Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study.
  • Subjects of must agree to use hormonal or two forms of nonhormonal during the study.
  • Female subjects must not be pregnant.
  • Be in good general health and expected to complete the clinical study as designed.
  • Have a (BMI) of 18 to 38 kg/m2 (both inclusive).
  • Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine.
  • Have a negative alcohol breath test at screening and study start.

Exclusion criteria

Exclusion Criteria:

  • Have an active unstable medical condition within 1 month (30 days) prior to screening.
  • Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary).
  • Have a known history of neuroleptic malignant syndrome.
  • Have a significant risk of suicidal or violent behavior.
  • Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine.
  • Receiving medication for the treatment of tardive dyskinesia.
  • Have a positive antibody, (HIV-Ab), surface antigen (HBsAg), or virus (HCV) antibody result at screening or have a history of positive result.
  • Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.
  • Have an allergy, , or intolerance to tetrabenazine.
  • Have had previous exposure with NBI-98854.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    NBI-98854 50 mg

    NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.

    Drug: NBI-98854

  • Experimental
    NBI-98854 100 mg and 50 mg

    NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.

    Drug: NBI-98854

  • Placebo comparator
    Placebo

    Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6

    The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity. The primary efficacy endpoint was the change from baseline in the AIMS dyskinesia total score at Week 6 between the pooled NBI-98854 50+100 mg group and placebo group analyzed using the ANCOVA model (LOCF, ITT analysis set).

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Clinical Global Impression - Global Improvement of TD (CGI-TD)

    Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse). The ANOVA analysis of CGI-TD was conducted for the pooled NBI-98854 50+100 mg group and placebo group.

    Time frame: Week 6

  2. Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 2

    Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

    Time frame: Week 2

07

Results

Posted Nov 8, 2017

Participant flow

This study enrolled patients with a clinical diagnosis of schizophrenia or schizoaffective disorder with moderate or severe tardive dyskinesia (TD) from 35 centers in the United States and Puerto Rico. The last patient completed in October 2013.

Double-Blind Period (Week 0 to 6)
Participant flow — Double-Blind Period (Week 0 to 6)
MilestoneDouble-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mg
Started542827
Completed472521
Not completed736
Withdrew: Adverse event101
Withdrew: Non-compliance123
Withdrew: Withdrawal by subject401
Withdrew: Lost to follow-up101
Withdrew: Physician decision010
Open-Label Period (Week 6 to 12)
Participant flow — Open-Label Period (Week 6 to 12)
MilestoneDouble-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mg
Started472521
Completed422217
Not completed534
Withdrew: Adverse event411
Withdrew: Non-compliance002
Withdrew: Withdrawal by subject120
Withdrew: Lost to follow-up001
Follow-up Period (Week 12 to 16)
Participant flow — Follow-up Period (Week 12 to 16)
MilestoneDouble-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mg
Started422217
Completed422117
Not completed010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryAbnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6

The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity. The primary efficacy endpoint was the change from baseline in the AIMS dyskinesia total score at Week 6 between the pooled NBI-98854 50+100 mg group and placebo group analyzed using the ANCOVA model (LOCF, ITT analysis set).

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6
units on a scalePlaceboAll Valbenazine
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6-2.5 ± 0.7-3.3 ± 0.7
Statistical analysis
  • Placebo vs All Valbenazine · ANCOVA · p = 0.2966 · Mean difference (final values): -0.8 · 95% CI -2.3 to 0.7
SecondaryClinical Global Impression - Global Improvement of TD (CGI-TD)

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse). The ANOVA analysis of CGI-TD was conducted for the pooled NBI-98854 50+100 mg group and placebo group.

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement of TD (CGI-TD)
units on a scalePlaceboValbenazine 50mg and Valbenazine 100mg Then 50mg
Clinical Global Impression - Global Improvement of TD (CGI-TD)3.2 ± 0.13.3 ± 0.1
Statistical analysis
  • Placebo vs Valbenazine 50mg and Valbenazine 100mg Then 50mg · ANOVA · p = 0.743 · Mean difference (final values): 0.1 · 95% CI -0.3 to 0.4
SecondaryClinical Global Impression - Global Improvement of TD (CGI-TD) at Week 2

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

Time frame:
Week 2
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 2
units on a scalePlaceboValbenazine 50mgValbenazine 100mg
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 23.6 ± 0.13.3 ± 0.23.2 ± 0.2
Statistical analysis
  • Placebo vs Valbenazine 50mg · ANOVA · p = 0.1151 · Mean difference (final values): -0.3 · 95% CI -0.7 to 0.1
  • Placebo vs Valbenazine 100mg · ANOVA · p = 0.0277 · Mean difference (final values): -0.4 · 95% CI -0.8 to 0.0

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind 50mg0/28 (0%)2/28 (7.1%)4/28 (14.3%)
Double-Blind 100mg/50mg0/27 (0%)0/27 (0%)3/27 (11.1%)
Double-Blind Placebo0/54 (0%)1/54 (1.9%)2/54 (3.7%)
Open-Label 50mg0/93 (0%)3/93 (3.2%)5/93 (5.4%)
Follow-Up0/80 (0%)0/80 (0%)1/80 (1.3%)
Most frequent serious events
Most frequent serious events
EventDouble-Blind 50mgDouble-Blind 100mg/50mgDouble-Blind PlaceboOpen-Label 50mgFollow-Up
FallInjury, poisoning and procedural complications1/280/270/540/930/80
Chest painGeneral disorders1/280/270/540/930/80
Schizophrenia, paranoid typePsychiatric disorders0/280/271/540/930/80
Schizoaffective disorderPsychiatric disorders0/280/270/541/930/80
BronchitisInfections and infestations0/280/270/541/930/80
SchizophreniaPsychiatric disorders0/280/270/541/930/80
Suicidal ideationPsychiatric disorders0/280/270/541/930/80
Most frequent other events
Most frequent other events
EventDouble-Blind 50mgDouble-Blind 100mg/50mgDouble-Blind PlaceboOpen-Label 50mgFollow-Up
FatigueGeneral disorders0/282/270/540/930/80
ArthralgiaMusculoskeletal and connective tissue disorders2/280/270/540/931/80
SomnolenceNervous system disorders2/281/270/540/930/80
Urinary tract infectionInfections and infestations0/281/272/545/930/80

Baseline characteristics

Safety analysis set (all randomized subjects who received at least 1 dose of study drug).

Age, Continuous
Age, Continuous(years)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Mean54.5 (27 to 76)55.5 (42 to 72)55.6 (28 to 77)55.0 (27 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Female208937
Male34201872
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Black or African American2912748
White23151957
Native Hawaiian or Other Pacific Islander1001
Other0101
American Indian or Alaska Native, Black1012
Body Mass Index
Body Mass Index(kg/m^2)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Mean28.71 (19.2 to 44.2)28.85 (18.5 to 42.6)26.39 (14.1 to 37.8)28.17 (14.1 to 44.2)
Age at Schizophrenia/Schizoaffective Disorder Diagnosis
Age at Schizophrenia/Schizoaffective Disorder Diagnosis(years)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Mean29.4 (10 to 68)29.7 (16 to 66)30.4 (17 to 66)29.7 (10 to 68)
Age at TD Diagnosis
Age at TD Diagnosis(years)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Mean46.9 (16 to 73)48.5 (37 to 67)47.5 (22 to 73)47.5 (16 to 73)
BPRS Total Score
BPRS Total Score(units on a scale)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Mean33.8 (20 to 48)32.6 (22 to 49)33.0 (21 to 49)33.3 (20 to 49)
Baseline AIMS Total Dyskinesia Score
Baseline AIMS Total Dyskinesia Score(units on a scale)Double-Blind Placebo, Then Open-Label 50mgDouble-Blind 50mg, Then Open-Label 50mgDouble-Blind 100mg/50mg, Then Open-Label 50mgTotal
Mean15.3 ± 4.414.6 ± 5.914.6 ± 4.715.0 ± 4.8
08

Study locations

51 sites
  • Little Rock, Arkansas 72211, United States
  • Anaheim, California 92804, United States
  • Carson, California 90746, United States
  • Colton, California 92324, United States
  • Costa Mesa, California 92626, United States
  • Downey, California 90241, United States
  • Fountain Valley, California 92708, United States
  • Glendale, California 91206, United States
  • National City, California 91950, United States
  • Oceanside, California 92056, United States
  • Paramount, California 90723, United States
  • San Bernardino, California 92408, United States
  • San Diego, California 92103, United States
  • San Diego, California 92108, United States
  • San Diego, California 92121, United States
  • San Diego, California 92123, United States
  • Santa Ana, California 92705, United States
  • Fort Lauderdale, Florida 33334, United States
  • Hialeah, Florida 33012, United States
  • Lauderhill, Florida 33319, United States
  • Melbourne, Florida 32901, United States
  • Miami Springs, Florida 33166, United States
  • North Miami, Florida 33161, United States
  • Orange City, Florida 32763, United States
  • Atlanta, Georgia 30342, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60640, United States
  • Schaumburg, Illinois 60194, United States
  • New Orleans, Louisiana 70114, United States
  • Shreveport, Louisiana 71104, United States
  • Baltimore, Maryland 21285, United States
  • Glen Burnie, Maryland 21061, United States
  • Saint Louis, Missouri 63118, United States
  • Saint Louis, Missouri 63141, United States
  • Toms River, New Jersey 08755, United States
  • Albany, New York 12208, United States
  • Brooklyn, New York 11203, United States
  • Wards Island, New York 10035, United States
  • Hope Mills, North Carolina 28348, United States
  • Beachwood, Ohio 44122, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Conshohocken, Pennsylvania 19428, United States
  • Charleston, South Carolina 29407, United States
  • Memphis, Tennessee 38119, United States
  • DeSoto, Texas 75115, United States
  • Irving, Texas 75062, United States
  • Bothell, Washington 98011, United States
  • Kirkland, Washington 98033, United States
  • Spokane, Washington 99204, United States
  • Caguas, 00725, Puerto Rico
  • San Juan, 00927, Puerto Rico
09

References and documents

Publications

  • Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry. 2020 Jan;35(1):69-79. doi: 10.1002/gps.5218. Epub 2019 Oct 31. PubMed 31617235 ↗
  • Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):61-68. PubMed 28839341 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Sep 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 4 years 2 months after primary completion. A results delay was requested in Oct 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Sep 19, 2012
Start
Sep 2012
Primary completionActual
Sep 2013
CompletionActual
Oct 2013
Results delay requested
Oct 2, 2014
Results first posted
Nov 8, 2017
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01688037
Responsible party
Sponsor
First posted
Sep 19, 2012
Start date
Sep 2012
Primary completion
Sep 2013
Completion
Oct 2013
Results posted
Nov 8, 2017
Last update
Nov 8, 2017

Study contacts

Chris O'Brien, MD
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion